Propanc Biopharma shares surge 51.52% premarket as PRP therapy shows 85% tumor inhibition and targets $3.25B pancreatic cancer market.

Propanc Biopharma surged 51.52% in premarket trading following the announcement of its lead proenzyme therapy PRP, a potential breakthrough for pancreatic cancer treatment. PRP demonstrated over 85% tumor growth inhibition in preclinical studies and holds FDA Orphan Drug Designation. The company highlighted PRP’s novel mechanism targeting cancer stem cells and its potential to address unmet needs in a $3.25 billion pancreatic cancer market projected to grow to $10.25 billion by 2034. A landmark Phase 1b First-In-Human trial, set to begin in 2026 at Melbourne’s Peter MacCallum Cancer Centre, marks the first human evaluation of PRP. Strengthened intellectual property and the therapy’s potential to reduce metastasis and improve patient outcomes further fueled investor optimism, aligning with the stock’s sharp premarket rise.